Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 4/20 | 0.37 |
| ▸ | MAOA | P21397 | 4/20 | 0.37 |
| ▸ | MAOB | P27338 | 4/20 | 0.37 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11169467 | 0.77 | LMNA (0.41) | ALDH1A1MAPTKDM4EGAAHPGD | |
| SCHEMBL10332615 | 0.68 | DDB1 (0.41) | ALDH1A1MAPTKDM4EHPGDUSP2 | |
| SCHEMBL9735953 | 0.64 | CHRNB2 (0.41) | KMT2AUSP2LMNAADORA3KDM1A | |
| SCHEMBL3961283 | 0.63 | MAPT (0.55) | ALDH1A1MAPTKDM4EGAAHPGD | |
| SCHEMBL11837569 | 0.63 | MAPT (0.42) | ALDH1A1MAPTKDM4EGAAHPGD | |
| SCHEMBL1895535 | 0.62 | MAPT (0.48) | ALDH1A1MAPTKDM4EGAAHPGD | |
| SCHEMBL936851 | 0.62 | MAPT (0.46) | ALDH1A1MAPTKDM4EGAAHPGD | |
| Methane SCHEMBL11336749 | 0.62 | MAPT (0.48) | ALDH1A1MAPTKDM4EGAAHPGD | |
| SCHEMBL1894049 | 0.62 | MAPT (0.48) | ALDH1A1MAPTKDM4EGAAHPGD | |
| SCHEMBL15669931 | 0.62 | MAPT (0.48) | ALDH1A1MAPTKDM4EGAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0150984-B1 | 6-(SUBSTITUTED) METHYLENEPENICILLANIC AND 6-(SUBSTITUTED) HYDROXYMETHYLPENICILLANIC ACIDS AND DERIVATIVES THEREOF | PFIZER INC. (US) | 1991-09-11 | — | — | EP | claimed |
| US-5015473-A | Beta-lactamase inhibitors | PFIZER INC. (US) | 1991-05-14 | — | — | US | claimed |
| US-4826833-A | ANTIBIOTICS | PFIZER INC. (US) | 1989-05-02 | — | — | US | claimed |
| EP-0150984-A2 | 6-(Substituted) methylenepenicillanic and 6-(substituted) hydroxymethylpenicillanic acids and derivatives thereof | PFIZER INC. (US) | 1985-08-07 | — | — | EP | claimed |
| EP-0061313-B1 | BIS-ESTERS OF 1,1-ALKANEDIOLS WITH 6-BETA-HYDROXYMETHYLPENICILLANIC ACID 1,1-DIOXIDE AND BETA-LACTAM ANTIBIOTICS | PFIZER INC. (US) | 1985-01-16 | — | — | EP | claimed |
| US-4342768-A | Bis-esters of 1,1-alkanediols with 6-beta-hydroxymethylpenicillanic acid 1,1-dioxide and beta-lactam antibiotics | PFIZER INC. (US) | 1982-08-03 | — | — | US | claimed |
| US-4159267-A | Novel silyl ester azetidine-2-sulfenate intermediates and process for preparing desacetoxycephalosporins | ELI LILLY AND COMPANY (US) | 1979-06-26 | — | — | US | claimed |
| US-3989685-A | FROM PENICILLIN-1-OXIDE | SHINOGI & CO., LTD. (JA) | 1976-11-02 | — | — | US | claimed |
| US-3944545-A | Process for preparing desacetoxycephalosporins | ELI LILLY AND COMPANY (US) | 1976-03-16 | — | — | US | claimed |
| US-20020068827-A1 | Quinoline-4-carboxamide derivatives, their preparation and their use as neurokinin 3 ( NK-3 ) - and neurokinin 2 ( NK-3 ) receptor antagonists | SMITHKLINE BEECHAM S.P.A. | 2002-06-06 | — | — | US | disclosed |
| EP-1019377-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS NEUROKININ 3 (NK-3)- AND NEUROKININ 2 (NK-2) RECEPTOR ANTAGONISTS. | Smithkline Beecham S.p.A. (IT) | 2000-07-19 | — | — | EP | disclosed |
| WO-1997019926-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS NEUROKININ 3 (NK-3)- AND NEUROKININ 2 (NK-2) RECEPTOR ANTAGONISTS. | SMITHKLINE BEECHAM S.P.A. (IT) | 1997-06-05 | — | — | WO | disclosed |
| EP-0150984-B1 | 6-(SUBSTITUTED) METHYLENEPENICILLANIC AND 6-(SUBSTITUTED) HYDROXYMETHYLPENICILLANIC ACIDS AND DERIVATIVES THEREOF | PFIZER INC. (US) | 1991-09-11 | — | — | EP | disclosed |
| US-5015473-A | Beta-lactamase inhibitors | PFIZER INC. (US) | 1991-05-14 | — | — | US | disclosed |
| US-4113940-A | ANTIMICROBIAL | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1978-09-12 | — | — | US | disclosed |
| US-4079181-A | INTERMEDIATES FOR 3-HYDROXY-3-CEPHEM COMPOUNDS | SHIONOGI & CO., LTD. (JA) | 1978-03-14 | — | — | US | disclosed |
| US-4053469-A | BACTERICIDES | SHIONOGI & CO., LTD. (JA) | 1977-10-11 | — | — | US | disclosed |
| US-3989685-A | FROM PENICILLIN-1-OXIDE | SHINOGI & CO., LTD. (JA) | 1976-11-02 | — | — | US | disclosed |
| US-3987039-A | ANTIBACTERIAL | SHIONOGI & CO., LTD. (JA) | 1976-10-19 | — | — | US | disclosed |
| US-3944545-A | Process for preparing desacetoxycephalosporins | ELI LILLY AND COMPANY (US) | 1976-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068827-A1 | Quinoline-4-carboxamide derivatives, their preparation and their use as neurokinin 3 ( NK-3 ) - and neurokinin 2 ( NK-3 ) receptor antagonists | TAC3, TACR2, TACR1 | ALDH1A1 2059/4885MAPT 4548/4885KDM4E 2406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.